Inc.

SMC Announces Marketing Agreement with Plato Technologies. Inc.

Source Node:
Time Stamp: April 19, 2024 5:45 AM - Modified On: April 19, 2024 - Published By:
Source Cluster:
Republished By Plato

  BOCA RATON, FL / Plato / Amplifi / April 18,2024 / SMC Entertainment, Inc. ("SMC" or the "Company") (OTC PINK: SMCE) SMC / (PINK:SMCE) is pleased to announce a marketing agreement and collaboration with Plato Technologies Inc. Plato Technologies specializes in AI content disruption and AI management systems. The collaboration will enable the Company to market Plato's platform directly to web and content development teams. The companies have agreed on a revenue sharing agreement after deducting individual client acquisition costs. "This is just the beginning." stated Erik Blum CEO

SUPER BOWL 2024: LAS VEGAS LEGENDS LIVE BRIDGING THE SUPERBOWL SPIRIT WITH A LEGENDARY EVENT AND METAVERSE INNOVATION

Source Node:
Time Stamp: January 9, 2024 10:02 AM - Modified On: January 9, 2024 - Published By:
Source Cluster:
Republished By Plato

Las Vegas, NV – January 9th 2024. As the Super Bowl fever grips Las Vegas, Legends Live is set to amplify this excitement with a one-of-a-kind event, Legends Live, on February 4th, 2024, at Vu Studios. This event, building up to the Super Bowl weekend, offers a unique blend of sports legends' stories and cutting-edge Metaverse streaming technology in partnership with TCG World. Legends Live presents a rare opportunity to hear from sports icons in the lead-up to one of the biggest sporting events of the year. The event will

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

TCG World Metaverse and Procedural Worlds Craft Vast and Vivid Landscapes with Groundbreaking Technology

Source Node:
Time Stamp: November 10, 2023 11:16 AM - Modified On: November 10, 2023 - Published By:
Source Cluster:
Republished By Plato

New York, November 11, 2023. In a landmark year of collaboration, TCG World Metaverse has joined forces with the talented team at Procedural Worlds to forge a sprawling and immersive environment within the burgeoning metaverse sector. Covering an impressive 900 square kilometers, TCG World has been meticulously sculpted into four distinct regions: North, East, Forest, and Asia. Each quadrant boasts its own unique biome and atmosphere, thanks to the innovative suite of tools provided by Procedural Worlds — Gaia, GeNa, and the revolutionary new software, Storm. Procedural Worlds' artisans have

Unveiling the Future of Gaming: Gaming Guilds Pioneer the Transition to the Metaverse with TCG World

Source Node:
Time Stamp: October 31, 2023 12:50 PM - Modified On: October 31, 2023 - Published By:
Source Cluster:
Republished By Plato

In a monumental leap towards the future of gaming, we are excited to announce that the world of gaming guilds is undergoing a revolutionary transformation with the advent of the metaverse. This virtual universe, composed of interconnected digital spaces, has opened the doors for gaming guilds to claim their stake in the burgeoning digital economy. With the upcoming launch of TCG World in 2024, the platform is setting the stage for this transformation. TCG World, a virtual world within the metaverse, has successfully registered over 30 gaming guilds with a

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

NEW APPEAL TO PROVIDE SUPPORT TO THOUSANDS OF ISRAELI CITIZENS FOLLOWING HAMAS ASSAULT

Source Node:
Time Stamp: October 19, 2023 12:35 PM - Modified On: October 19, 2023 - Published By:
Source Cluster:
Republished By Plato

  Tel Aviv, New York & London; October 19, 2023: In the wake of the recent catastrophic and unprecedented attack that was launched at Israel by Hamas on and beyond October 7, Ahavat Yisroel Humanity Inc. has launched an urgent fundraising appeal in order to provide much-needed support and supplies to the thousands of Israeli citizens affected. The Israel Now, Israel Forever appeal is seeking donations to provide the many affected citizens with food, shelter, and urgent suppliers. The donations will be shared among four established and experienced relief organisations

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Clinical Squared and PlatoHealth Join Forces to Revolutionize Healthcare with Advanced Data Orchestration Powered by AI.

Source Node:
Time Stamp: September 20, 2023 12:28 PM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington DC, September 20th, 2023 — Clinical Squared (C2) and Platohealth.ai are delighted to announce a groundbreaking partnership that promises to reshape the healthcare landscape. Their collaboration brings together the healthcare expertise of C2 and the cutting-edge AI and machine learning capabilities of Plato.ai to create innovative solutions. [gallery columns="2" link="none" size="large" ids="2281765,2281767"] Clinical Squared, a leader in healthcare market expertise, data architecture, software development, consultation and implementation services, will lend its extensive industry knowledge to Plato.ai's platform. In turn, Plato.ai will provide advanced AI and machine learning mechanisms to

Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications

Source Node:
Time Stamp: September 20, 2023 8:36 AM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety ORLANDO, FL / September 20, 2023 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches. The newly granted patent, numbered U.S. patent 11,759,431, titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Source Node:
Time Stamp: August 29, 2023 11:37 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement